Neuroscience

Biosynthetic Pathway Discovery for β-Carbolines in Ayahuasca Plants

New research enables controlled production of β-carbolines and DMT in model plants, paving the way for standardized ayahuasca research, sustainable sourcing, and pharmaceutical innovation.

Published November 19, 2026 Read 3 min 724 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Discovery of the β-Carboline Biosynthetic Pathway in Ayahuasca Plants

Researchers have identified the complete biosynthetic pathway for β-carbolines, the key alkaloids in ayahuasca, enabling their controlled production in model plants. This work, published on November 19, 2026 (OpenAlex), reveals how specific enzymes in Peganum harmala and model species like Nicotiana benthamiana can be harnessed to produce harmine and related compounds, as well as N,N-dimethyltryptamine (DMT), the primary psychoactive ingredient in ayahuasca.

Ayahuasca is a traditional Amazonian brew combining DMT-containing plants (often Psychotria viridis) with β-carboline-rich Banisteriopsis caapi. β-Carbolines such as harmine inhibit monoamine oxidases (MAOs), allowing DMT to become orally active. Until now, the precise biosynthetic steps for β-carbolines in plants were unresolved, limiting efforts to produce these compounds sustainably and reproducibly for research or therapeutic use.

Mechanism and Experimental Approach

The researchers used spatial metabolite profiling, transcriptome analysis, enzyme characterization, and pathway reconstruction to map the biosynthetic steps for harmine. They identified four key enzymes responsible for de novo harmine biosynthesis in N. benthamiana. Notably, two closely related cytochrome P450 enzymes were found to direct tryptamine metabolism toward either β-carboline or serotonin, depending on subtle differences in their active sites.

Through structural modeling and targeted mutagenesis, the team pinpointed amino acid residues that control this regioselectivity. By engineering these enzymes, they enabled the co-production of β-carbolines and DMT in both N. benthamiana and P. harmala hairy root cultures, without the need for externally supplied precursors. This achievement provides a platform for producing standardized plant-derived ayahuasca alkaloids for research and potential pharmaceutical applications.

Policy, Research, and Industry Implications

The ability to biosynthetically produce β-carbolines and DMT in model plants has significant implications for psychedelic research, clinical trials, and industry. Standardized, reproducible production of these compounds could address a major challenge in current clinical studies: variability in the composition of plant-derived ayahuasca brews. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) require consistent, well-characterized materials for investigational new drug (IND) applications and clinical trial approvals.

This breakthrough may also reduce reliance on wild-harvested ayahuasca plants, supporting biodiversity conservation and mitigating the risk of overharvesting in the Amazon. Pharmaceutical developers could use engineered crops or bioreactors to produce clinical-grade β-carbolines and DMT, facilitating research into their pharmacology, safety, and therapeutic potential. For indigenous communities and conservationists, the technology presents both opportunities and challenges regarding intellectual property, benefit sharing, and cultural heritage.

Risks, Unknowns, and Ethical Considerations

While the discovery offers clear benefits, it also raises important questions about safety, regulation, and ethics. The pharmacology of ayahuasca is complex, involving multiple alkaloids and plant constituents; reproducing only β-carbolines and DMT may not fully capture the brew's effects or risks. Further, the introduction of engineered alkaloid biosynthesis into crops or bioreactors could present biosecurity and diversion concerns, requiring oversight from agencies such as the U.S. Drug Enforcement Administration (DEA) and international counterparts.

Ethical considerations include the potential commodification of traditional knowledge and the need for equitable benefit sharing with Amazonian indigenous communities. Intellectual property rights over biosynthetic genes and engineered pathways may also become contentious, especially if commercialized without appropriate consent or compensation.

A non-obvious risk is that over-reliance on biosynthesized alkaloids could inadvertently narrow research focus to a subset of ayahuasca's constituents, overlooking the possible contributions of minor compounds or plant matrix effects. This could limit understanding of both therapeutic efficacy and adverse event profiles in clinical settings.

Outlook and Next Steps

The elucidation of the β-carboline biosynthetic pathway marks a pivotal advance for psychedelic science, but its full impact will depend on responsible implementation and continued research. Immediate next steps include optimizing production yields, verifying the pharmacological equivalence of biosynthesized versus naturally derived alkaloids, and engaging with regulatory agencies to define standards for clinical use.

Longer-term, this technology could support large-scale clinical trials, novel drug discovery, and sustainable supply chains for psychedelic-assisted therapies. However, stakeholders must address unresolved questions around regulation, ethics, and indigenous rights to ensure that scientific progress benefits all parties and respects cultural heritage.

Byline: Dr. Emily Carter, PhD (Neuropharmacology), Psychedelic Research Journal. Reviewed by Dr. Rafael Silva, MD, November 2026. Research based on primary publication: OpenAlex W7236816159.

Primary source: https://openalex.org/W7236816159 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.